Evoke, EVERSANA announce statistically significant improvement using GIMOTI

Evoke Pharma (EVOK) together with EVERSANA announced the presentation of data for GLP-1 users with diabetic gastroparesis using GIMOTI at the American College of Gastroenterology, ACG, 2024 Annual Meeting. Key Study Findings Presented at ACG 2024: Patients with prior GLP-1 history had reduced HRU after taking NMCP – in NMCP patients, all-cause emergency department visits decreased by 55% and DGP-related ED visits decreased by 28%. In patients taking GLP-1, those that took NMCP had fewer healthcare visits compared to those taking OMCP – All-cause and DGP-related ED visits were 91% lower for NMCP vs. OMCP; and All-cause Hospital Outpatient visits were 89% lower, All-cause and DGP-related office visits were 41% lower and 66% lower for NMCP vs. OMCP. NMCP can be used to effectively treat patients with gastroparesis taking GLP-1 treatment and avoid costly healthcare visits – All-cause clinic, outpatient, and inpatient visits showed similar trends favoring NMCP vs. OMCP. In DGP patients with a prior claim for GLP-1, NMCP use was associated with numerically and significantly reduced all-cause and DGP-related HRU compared to pre-treatment utilization and OMCP-treated controls.